Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 124, Issue 9
August 28 2014
Issue Cover

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Microbial messaging to the marrow
Stephanie S. Watowich
View Articletitled, Microbial messaging to the marrow
INSIDE BLOOD COMMENTARY
The clinical path to integrated genomics in ALL
Clinical Trials & Observations
Jean-Pierre Bourquin
View Articletitled, The clinical path to integrated genomics in ALL
INSIDE BLOOD COMMENTARY
ASXL genes and RUNX1: an intimate connection?
Clinical Trials & Observations
Klaus H. Metzeler
View Articletitled, <em>ASXL</em> genes and <em>RUNX1</em>: an intimate connection?
INSIDE BLOOD COMMENTARY
Take (STAT)5: jazzing up T-cell leukemia
Pierluigi Porcu,Jason Dubovsky
View Articletitled, Take (STAT)5: jazzing up T-cell leukemia
INSIDE BLOOD COMMENTARY
What is a true ALCL?
Wolfram Klapper
View Articletitled, What is a true ALCL?
INSIDE BLOOD COMMENTARY
Targeting the JAK2-STAT5 pathway in CML
Peter Valent
View Articletitled, Targeting the JAK2-STAT5 pathway in CML
INSIDE BLOOD COMMENTARY
Look out heme, Mac is back in town
Gregory M. Vercellotti
View Articletitled, Look out heme, Mac is back in town
INSIDE BLOOD COMMENTARY
Primetime for γ′
David H. Farrell
View Articletitled, Primetime for γ′

BLOOD WORK

Abnormal lymphocytes with “filamentous-like” cytoplasmic inclusions in chronic lymphocytic leukemia
Richard Torres,Christopher A. Tormey
View Articletitled, Abnormal lymphocytes with “filamentous-like” cytoplasmic inclusions in chronic lymphocytic leukemia
Nuclear hypersegmentation of neutrophils, eosinophils, and basophils due to hydroxycarbamide (hydroxyurea)
Xiangdong Xu
View Articletitled, Nuclear hypersegmentation of neutrophils, eosinophils, and basophils due to hydroxycarbamide (hydroxyurea)

PLENARY PAPER

Endothelial cells translate pathogen signals into G-CSF–driven emergency granulopoiesis
Steffen Boettcher,Rahel C. Gerosa,Ramin Radpour,Judith Bauer,Franziska Ampenberger,Mathias Heikenwalder,Manfred Kopf,Markus G. Manz
View Articletitled, Endothelial cells translate pathogen signals into G-CSF–driven emergency granulopoiesis
Supplemental data

REVIEW ARTICLE

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios A. Dimopoulos,Efstathios Kastritis,Roger G. Owen,Robert A. Kyle,Ola Landgren,Enrica Morra,Xavier Leleu,Ramón García-Sanz,Nikhil Munshi,Kenneth C. Anderson,Evangelos Terpos,Irene M. Ghobrial,Pierre Morel,David Maloney,Mathias Rummel,Véronique Leblond,Ranjana H. Advani,Morie A. Gertz,Charalampia Kyriakou,Sheeba K. Thomas,Bart Barlogie,Stephanie A. Gregory,Eva Kimby,Giampaolo Merlini,Steven P. Treon
View Articletitled, Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
von Willebrand factor, Jedi knight of the bloodstream
Timothy A. Springer
View Articletitled, von Willebrand factor, Jedi knight of the bloodstream
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Clinical Trials & Observations
Hartmut Döhner,Michael Lübbert,Walter Fiedler,Loic Fouillard,Alf Haaland,Joseph M. Brandwein,Stephane Lepretre,Oumedaly Reman,Pascal Turlure,Oliver G. Ottmann,Carsten Müller-Tidow,Alwin Krämer,Emmanuel Raffoux,Konstanze Döhner,Richard F. Schlenk,Florian Voss,Tillmann Taube,Holger Fritsch,Johan Maertens
View Articletitled, Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Supplemental data
A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia
Clinical Trials & Observations
Anthony V. Moorman,Amir Enshaei,Claire Schwab,Rachel Wade,Lucy Chilton,Alannah Elliott,Stacey Richardson,Jeremy Hancock,Sally E. Kinsey,Christopher D. Mitchell,Nicholas Goulden,Ajay Vora,Christine J. Harrison
View Articletitled, A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia
Supplemental data
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations
Clinical Trials & Observations Brief Report
Jean-Baptiste Micol,Nicolas Duployez,Nicolas Boissel,Arnaud Petit,Sandrine Geffroy,Olivier Nibourel,Catherine Lacombe,Helene Lapillonne,Pascaline Etancelin,Martin Figeac,Aline Renneville,Sylvie Castaigne,Guy Leverger,Norbert Ifrah,Hervé Dombret,Claude Preudhomme,Omar Abdel-Wahab,Eric Jourdan
View Articletitled, Frequent <em>ASXL2</em> mutations in acute myeloid leukemia patients with t(8;21)/<em>RUNX1-RUNX1T1</em> chromosomal translocations
Supplemental data

IMMUNOBIOLOGY

Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity
Catalina Lee-Chang,Monica Bodogai,Kanako Moritoh,Purevdorj B. Olkhanud,Andrew C. Chan,Michael Croft,Julie A. Mattison,Peter Johannes Holst,Ronald E. Gress,Luigi Ferrucci,Fran Hakim,Arya Biragyn
View Articletitled, Accumulation of 4-1BBL<sup>+</sup> B cells in the elderly induces the generation of granzyme-B<sup>+</sup> CD8<sup>+</sup> T cells with potential antitumor activity
Supplemental data

LYMPHOID NEOPLASIA

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
Mark J. Kiel,Thirunavukkarasu Velusamy,Delphine Rolland,Anagh A. Sahasrabuddhe,Fuzon Chung,Nathanael G. Bailey,Alexandra Schrader,Bo Li,Jun Z. Li,Ayse B. Ozel,Bryan L. Betz,Roberto N. Miranda,L. Jeffrey Medeiros,Lili Zhao,Marco Herling,Megan S. Lim,Kojo S. J. Elenitoba-Johnson
View Articletitled, Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia
Supplemental data
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Clinical Trials & Observations
Edgardo R. Parrilla Castellar,Elaine S. Jaffe,Jonathan W. Said,Steven H. Swerdlow,Rhett P. Ketterling,Ryan A. Knudson,Jagmohan S. Sidhu,Eric D. Hsi,Shridevi Karikehalli,Liuyan Jiang,George Vasmatzis,Sarah E. Gibson,Sarah Ondrejka,Alina Nicolae,Karen L. Grogg,Cristine Allmer,Kay M. Ristow,Wyndham H. Wilson,William R. Macon,Mark E. Law,James R. Cerhan,Thomas M. Habermann,Stephen M. Ansell,Ahmet Dogan,Matthew J. Maurer,Andrew L. Feldman
View Articletitled, ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Supplemental data
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
Dalia El-Gamal,Katie Williams,Taylor D. LaFollette,Matthew Cannon,James S. Blachly,Yiming Zhong,Jennifer A. Woyach,Erich Williams,Farrukh T. Awan,Jeffrey Jones,Leslie Andritsos,Kami Maddocks,Chia-Hsien Wu,Ching-Shih Chen,Amy Lehman,Xiaoli Zhang,Rosa Lapalombella,John C. Byrd
View Articletitled, PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
Supplemental data

MYELOID NEOPLASIA

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Paolo Gallipoli,Amy Cook,Susan Rhodes,Lisa Hopcroft,Helen Wheadon,Anthony D. Whetton,Heather G. Jørgensen,Ravi Bhatia,Tessa L. Holyoake
View Articletitled, JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34<sup>+</sup> cells in vitro and in vivo
Supplemental data
Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias
Alex Yick-Lun So,Reeshelle Sookram,Aadel A. Chaudhuri,Aarathi Minisandram,David Cheng,Catherine Xie,Ee Lyn Lim,Yvette Garcia Flores,Shuai Jiang,Jocelyn Tammy Kim,Christopher Keown,Parameswaran Ramakrishnan,David Baltimore
View Articletitled, Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias
Supplemental data
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
Luca Malcovati,Elli Papaemmanuil,Ilaria Ambaglio,Chiara Elena,Anna Gallì,Matteo G. Della Porta,Erica Travaglino,Daniela Pietra,Cristiana Pascutto,Marta Ubezio,Elisa Bono,Matteo C. Da Vià,Angela Brisci,Francesca Bruno,Laura Cremonesi,Maurizio Ferrari,Emanuela Boveri,Rosangela Invernizzi,Peter J. Campbell,Mario Cazzola
View Articletitled, Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Wild-type macrophages reverse disease in heme oxygenase 1-deficient mice
Gennadiy Kovtunovych,Manik C. Ghosh,Wade Ollivierre,R. Patrick Weitzel,Michael A. Eckhaus,John F. Tisdale,Akihiro Yachie,Tracey A. Rouault
View Articletitled, Wild-type macrophages reverse disease in heme oxygenase 1-deficient mice
Supplemental data

THROMBOSIS AND HEMOSTASIS

Fibrinogen γ′ increases the sensitivity to activated protein C in normal and factor V Leiden plasma
Farida Omarova,Shirley Uitte de Willige,Paolo Simioni,Robert A. S. Ariëns,Rogier M. Bertina,Jan Rosing,Elisabetta Castoldi
View Articletitled, Fibrinogen γ′ increases the sensitivity to activated protein C in normal and factor V Leiden plasma

ERRATA

Bernstein SH, Venkatesh S, Li M, et al. The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives. Blood. 2012;119(14):3321-3329.
View Articletitled, Bernstein SH, Venkatesh S, Li M, et al. The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives. <em>Blood.</em> 2012;119(14):<span class="related-article">3321-3329</span>.
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals